Loading...
XLON
PRM
Market cap15mUSD
May 19, Last price  
4.00GBP
1D
8.11%
1Q
-10.91%
Jan 2017
-27.27%
Name

Proteome Sciences PLC

Chart & Performance

D1W1MN
XLON:PRM chart
P/E
—
P/S
234.83
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-55.74%
Rev. gr., 5y
-80.88%
Revenues
5m
-99.98%
72,97016,00068,000266,000849,0001,306,0009,980,0001,021,0001,152,96724,870,000,00019,008,000,00019,641,000,00019,818,000,00018,927,000,00019,668,000,00019,730,000,00016,945,000,00022,593,000,00023,736,000,0005,028,000
Net income
-2m
L
-5,199,260-6,897,000-5,638,000-5,252,000-4,624,000-4,010,0004,563,000-3,957,000-4,253,594540,000,000-453,000,000-626,000,0001,562,000,000587,000,0001,597,000,0002,461,000,0001,526,000,0006,205,000,0005,023,000,000-2,443,000
CFO
-481k
L
-3,770,180-4,769,000-3,606,000-4,093,000-4,122,000-2,972,0004,003,000-5,166,000-3,353,367-11,550,000,000-6,267,000,00046,633,000,000-31,695,000,00055,473,000,000-14,780,000,000-21,451,000,000-7,744,000,00010,522,000,0003,882,000,000-481,000
Earnings
Sep 11, 2025

Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
URL
https://www.proteomics.com/
IPO date
Oct 03, 1995
Employees
27
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,028
-99.98%
23,736,000
5.06%
Cost of revenue
7,286
2,449,389
Unusual Expense (Income)
NOPBT
(2,258)
21,286,611
NOPBT Margin
89.68%
Operating Taxes
25
1,039,000
Tax Rate
4.88%
NOPAT
(2,283)
20,247,611
Net income
(2,443)
-100.05%
5,023,000
-19.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,491,000
9,014,000
BB yield
-83,341.66%
Debt
Debt current
11,844
11,562
Long-term debt
3,871
139,918,353
Deferred revenue
Other long-term liabilities
419
(139,918,000)
Net debt
13,688
(112,964,085)
Cash flow
Cash from operating activities
(481)
3,882,000
CAPEX
(237)
(1,746,000)
Cash from investing activities
(424)
(21,673,000)
Cash from financing activities
(1,062)
27,045,000
FCF
3,604,134
20,184,611
Balance
Cash
2,027
252,894,000
Long term investments
Excess cash
1,776
251,707,200
Stockholders' equity
(65,287)
57,767,526
Invested Capital
76,115
(62,361,531)
ROIC
0.01%
ROCE
1.41%
EV
Common stock shares outstanding
295,182
309,021
Price
0.04
-31.71%
Market cap
10,816
-30.09%
EV
(111,985,269)
EBITDA
(1,774)
22,013,611
EV/EBITDA
Interest
797
473
Interest/NOPBT
0.00%